BioSpace News Archive

Here are 7 self reflection questions to ask yourself during the New Year to find out if you’re on the right path to achieving your career goals in the coming year.

On Tuesday, Sandoz AG, Novartis’ subsidiary focused on generic drugs and biosimilars, teamed up with Tilray Canada, Ltd., a subsidiary of Tilray Inc. to increase availability of high quality medical cannabis products across the globe.

With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.

Researchers at the University of Wisconsin-Madison have developed a battery-free, easily implantable device, about a third the size of a penny, that helped laboratory rats lose weight.

With the holidays upon us, along with the end of 2018 and the beginning of 2019, the FDA squeezed some target action dates into the last weeks and beginning of the new year. As it turned out, these appear to be a mixed bag of extensions, resubmissions and supplemental applications, some of which are still pending while others have been approved earlier. Here’s a look.

Paris-based Sanofi announced it was transferring its listing of American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market starting end-of-day December 31, 2018. They will start trading on January 2, 2019.

Shares of the company stock plunged in premarket trading after Surface Oncology announced it was scaling back its lead program.

Under the terms of the agreement, Pfizer will combine its consumer healthcare business with GSK’s existing consumer healthcare business. The combined global sales were about $12.7 billion last year. Closing is expected in the second half of 2019, dependent on GSK’s shareholder approval and regulatory approvals.

As news continues about Johnson & Johnson’s talcum powder containing carcinogenic asbestos, more than 100 drug inspectors in India are seizing samples, characterized The Times of India. The company, however, downplays that description, suggesting that the samples are fairly routine.

Those 10 drugs that were launched over the past five years are expected to account for more than 45 percent of human pharmaceutical sales in 2019, Joshua Smiley, Lilly’s chief financial officer said.